RAPID RESPONSE TO FLUOXETINE IN WOMEN WITH PREMENSTRUAL DYSPHORIC DISORDER
- 4 May 2012
- journal article
- research article
- Published by Hindawi Limited in Depression and Anxiety
- Vol. 29 (6) , 531-540
Abstract
Background Selective serotonin reuptake inhibitors (SRIs) relieve irritability within days in women with premenstrual dysphoric disorder (PMDD); however, the effects on other affective symptoms in PMDD remain to be demonstrated. Methods We performed hourly ratings in women with PMDD to test the specificity of the therapeutic effects of SRIs and to determine whether the kinetics of these effects differ from those of the symptom offset accompanying menses. Twelve women with PMDD received fluoxetine (20 mg daily) during the luteal phase of the menstrual cycle. Twelve other women with PMDD received no treatment. Outcome measures included a visual analogue scale completed hourly before and after either the start of SRIs or at menses‐onset in the untreated women and the premenstrual tension syndrome (PMTS) scale completed daily. Data were analyzed by ANOVA‐R. Results Hourly VAS scores significantly improved after SRI in irritability as well as sadness, anxiety, and mood swings. Compared with the symptomatic pretreatment baseline, PMTS scores significantly improved on the second day after the start of SRI (p < .01). An identical time course of symptom improvement occurred after both SRI and menses‐onset. Conclusion and Discussion These data document that the rapid response to SRI was not limited to irritability. The similar kinetics in the remission of PMDD after SRIs and after menses‐onset suggest both a phenotype reflecting the relative capacity to rapidly change affective state, and a possible therapeutic mechanism by which SRIs recruit this endogenous capacity to change state, normally expressed around menses‐onset in women with PMDD.Keywords
This publication has 33 references indexed in Scilit:
- Selective Serotonin Reuptake Inhibitors for Premenstrual Syndrome and Premenstrual Dysphoric DisorderObstetrics & Gynecology, 2008
- Escitalopram Administered in the Luteal Phase Exerts a Marked and Dose-Dependent Effect in Premenstrual Dysphoric DisorderJournal of Clinical Psychopharmacology, 2008
- Serotonergic Modulation of GABAergic and Glutamatergic Synaptic Transmission in Mechanically Isolated Rat Medial Preoptic Area NeuronsNeuropsychopharmacology, 2007
- Low-Dose Sertraline in the Treatment of Moderate-to-Severe Premenstrual SyndromeThe Journal of Clinical Psychiatry, 2006
- Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptakePsychopharmacology, 2006
- Continuous or Intermittent Dosing With Sertraline for Patients With Severe Premenstrual Syndrome or Premenstrual Dysphoric DisorderAmerican Journal of Psychiatry, 2004
- Luteal Phase Sertraline Treatment for Premenstrual Dysphoric Disorder: Results of a Double-blind, Placebo-Controlled, Crossover StudyArchives of Family Medicine, 1999
- Effect of Menstrual Cycle Phase on Neuroendocrine and Behavioral Responses to the Serotonin Agonist m-Chlorophenylpiperazine in Women with Premenstrual Syndrome and ControlsThe Journal of Clinical Endocrinology & Metabolism, 1997
- The premenstrual syndrome – a reappraisal of the concept and the evidencePsychological Medicine. Monograph Supplement, 1993
- Lack of Effect of Induced Menses on Symptoms in Women with Premenstrual SyndromeNew England Journal of Medicine, 1991